The company plans to make the diagnostic available to physicians and researchers this summer, expanding its portfolio beyond ...

Fujirebio submitted a regulatory filing with the FDA in September for its test. It is the first commercially available blood-based in vitro diagnostic test for assessing Alzheimer’s in the U.S.

A first-of-its-kind blood test developed by Malvern-based Fujirebio Diagnostics to help diagnose Alzheimer’s disease has received clearance from the U.S. Food and Drug Administration, writes ...

Fujirebio Diagnostics designed the blood test to help detect Alzheimer’s disease early, when interventions are more effective, the president and CEO Monte Wiltse said in a news release last ...

Neurologists diagnose cognitive impairment with a clinical exam of memory and thinking skills. To determine whether Alzheimer ...

--Biogen Inc., Beckman Coulter, Inc. and Fujirebio announced a collaboration to potentially identify and develop blood-based biomarkers for tau pathology in the brain and to potentially clinically ...

Collaboration Builds upon Fujirebio Expertise in Neurodegenerative Disease Assays and Beckman Coulter's High Sensitivity, High Throughput, Global Installed Base of Access Family of Immunoassay ...

Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. | The Lumipulse G blood test measures the ratio between ...

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...

Fujirebio Diagnostics designed the blood test to help detect Alzheimer’s disease early, when interventions are more effective, the president and CEO Monte Wiltse said in a news release last ...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the ...